AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca other Rare Disease medicines — Worldwide product sales ($M) ($M)
Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables
Latest, FY2025
231
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 6-K FY2025Q4 Earnings Release
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Rare Disease medicines — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 231 | – | Form 6-K FY2025Q4 Earnings Release ↗ |
Breakdown
What makes up other rare disease medicines — worldwide product sales ($m)
- Other Rare Disease medicines — Worldwide YoY actual (%)11.0% · FY2025
- Other Rare Disease medicines — Worldwide YoY CER (%)10.0% · FY2025
- Other Rare Disease medicines — US product sales ($M)113 · FY2025
- Other Rare Disease medicines — Emerging Markets product sales ($M)40 · FY2025
- Other Rare Disease medicines — Europe product sales ($M)67 · FY2025
- Other Rare Disease medicines — Established RoW product sales ($M)11 · FY2025
Cite this data
StockData. (2026). AstraZeneca Other Rare Disease medicines — Worldwide product sales ($M) ($M), annual FY2025–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_other_rare_world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.